Recent News

• 03.06.2026 - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.03.2026 - Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
• 03.02.2026 - Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
• 02.26.2026 - Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
• 02.24.2026 - Intellia Therapeutics to Participate in Upcoming Investor Conferences
• 02.19.2026 - Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Recent Filings

• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.02.2026 - 8-K Current report
• 03.02.2026 - EX-99.1 EX-99.1
• 03.02.2026 - 424B5 Prospectus [Rule 424(b)(5)]